{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:40:33Z","timestamp":1733226033453,"version":"3.30.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.xcrm.2024.101425","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T15:45:53Z","timestamp":1708443953000},"page":"101425","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opening the KV3.1 gates: A therapeutic strategy for progressive myoclonus epilepsy type 7?"],"prefix":"10.1016","volume":"5","author":[{"given":"Maria A.","family":"Gandini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald W.","family":"Zamponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101425_bib1","article-title":"Targeted therapy improves cellular dysfunction, ataxia, and seizure susceptibility in a model of a progressive myoclonus epilepsy","volume":"5","author":"Feng","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2024.101425_bib2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1113\/jphysiol.2010.190652","article-title":"Neurological channelopathies: new insights into disease mechanisms and ion channel function","volume":"588","author":"Kullmann","year":"2010","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.xcrm.2024.101425_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.24929","article-title":"Myoclonus epilepsy and ataxia due to KCNC1 mutation: Analysis of 20 cases and K(+) channel properties","volume":"81","author":"Oliver","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2024.101425_bib4","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/acn3.50822","article-title":"Encephalopathies with KCNC1 variants: genotype-phenotype-functional correlations","volume":"6","author":"Cameron","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.xcrm.2024.101425_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ng.3144","article-title":"A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy","volume":"47","author":"Muona","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2024.101425_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1684\/epd.2016.0859","article-title":"Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations","volume":"18","author":"Nascimento","year":"2016","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.xcrm.2024.101425_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.101897","article-title":"Generation of induced pluripotent stem cell GZHMCi001-A and GZHMCi001-B derived from peripheral blood mononuclear cells of epileptic patients with KCNC1 mutation","volume":"47","author":"Nengqing","year":"2020","journal-title":"Stem Cell Res."},{"year":"2017","series-title":"AUT00206, a Kv3 Channel Modulator with Potential for the Treatment of Fragile X Syndrome","author":"Large","key":"10.1016\/j.xcrm.2024.101425_bib8"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912400048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912400048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T10:58:21Z","timestamp":1733223501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912400048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S266637912400048X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101425","relation":{},"ISSN":["2666-3791"],"issn-type":[{"type":"print","value":"2666-3791"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opening the KV3.1 gates: A therapeutic strategy for progressive myoclonus epilepsy type 7?","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101389","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101425"}}